Published in Ann N Y Acad Sci on March 23, 2016
Hematological disorders and pulmonary hypertension. World J Cardiol (2016) 0.75
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med (2002) 7.59
A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med (2011) 7.21
Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ (2008) 7.19
The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA (2005) 6.49
Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA (2005) 6.14
Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med (2013) 5.60
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med (2013) 5.22
Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med (1993) 4.91
Beta-thalassemia. N Engl J Med (2005) 4.22
Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol (2004) 3.63
Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med (2000) 3.57
The beta-thalassemias. N Engl J Med (1999) 3.19
An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest (2012) 2.82
Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica (2005) 2.64
Endothelins. N Engl J Med (1995) 2.52
Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood (2007) 2.31
Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost (2006) 2.27
The hypercoagulable state in thalassemia. Blood (2002) 1.88
Right ventricular cardiomyopathy in beta-thalassaemia major. Eur Heart J (2002) 1.88
Pulmonary hypertension and right heart failure in patients with beta-thalassemia intermedia. Chest (1995) 1.78
Marrow transplantation for thalassaemia. Lancet (1982) 1.71
Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood (1996) 1.70
Cardiac involvement in thalassemia intermedia: a multicenter study. Blood (2001) 1.67
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood (2011) 1.64
How I treat thalassemia. Blood (2011) 1.58
Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol (2000) 1.56
Pulmonary function abnormalities in thalassemia major and the role of iron overload. Am J Respir Crit Care Med (1994) 1.48
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol (2005) 1.47
Cardiac status in well-treated patients with thalassemia major. Eur J Haematol (2004) 1.41
Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med (2001) 1.40
Mechanisms of NO/cGMP-dependent vasorelaxation. Circ Res (2000) 1.36
Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci (2005) 1.36
Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci (2005) 1.35
Hydrops fetalis caused by alpha-thalassemia: an emerging health care problem. Blood (1998) 1.33
Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol (2010) 1.25
Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res (2013) 1.23
Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases. Hemoglobin (2008) 1.23
Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Int J Hematol (2003) 1.23
HLA-matched sibling bone marrow transplantation for β-thalassemia major. Blood (2010) 1.20
Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ Heart Fail (2010) 1.19
Left ventricular diastolic Doppler characteristics in beta-thalassemia major. Circulation (1993) 1.19
Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant Group. Ann N Y Acad Sci (2005) 1.18
Arterial stiffness and endothelial function in patients with beta-thalassemia major. Circulation (2002) 1.10
The α-thalassemias. N Engl J Med (2014) 1.10
Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther (2004) 1.08
Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: a Webthal study. Circulation (2013) 1.06
Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. Blood (2002) 1.05
Redefining thalassemia as a hypercoagulable state. Ann N Y Acad Sci (2010) 1.04
Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. Br J Haematol (2009) 1.03
Enhanced aggregability of red blood cells of beta-thalassemia major patients. Am J Physiol (1996) 1.02
In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major. Br J Haematol (1997) 1.02
Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica (2007) 1.00
Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia. Heart (2006) 1.00
Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica (2013) 0.99
Pulmonary hypertension in beta-thalassemia. Ann N Y Acad Sci (2005) 0.95
Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrinolysis (1995) 0.95
Pulmonary hypertension in thalassaemia major patients with normal left ventricular systolic function. Br J Haematol (2006) 0.93
Reduced intensity stem cell transplantation for treatment of class 3 Lucarelli severe thalassemia patients. Am J Hematol (2007) 0.93
Pulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication? Hemoglobin (2002) 0.92
Pulmonary hypertension, interstitial lung fibrosis, and lung iron deposition in thalassaemia major. Thorax (2001) 0.90
Utility of phase contrast MR imaging for assessment of pulmonary flow and pressure estimation in patients with pulmonary hypertension: comparison with right heart catheterization and echocardiography. J Magn Reson Imaging (2009) 0.89
Pulmonary hypertension in beta-thalassemia major and the role of L-carnitine therapy. Pediatr Hematol Oncol (2008) 0.89
Lung function in beta-thalassemia patients: a longitudinal study. Acta Haematol (2006) 0.89
Pulmonary function testing in patients with pulmonary arterial hypertension. Respir Med (2009) 0.86
Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension. Blood (2012) 0.84
Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients. Bone Marrow Transplant (2011) 0.84
The cure of the thalassemia with bone marrow transplantation. Bone Marrow Transplant (2001) 0.83
Pulmonary dysfunction in transfusion-dependent patients with thalassemia major. Am J Respir Crit Care Med (2003) 0.82
Hypercoagulable state and methylenetetrahydrofolate reductase (MTHFR) C677T mutation in patients with beta-thalassemia major in Kuwait. Acta Haematol (2009) 0.82
Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011. Exp Hematol Oncol (2012) 0.82
Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature. Am J Hematol (2006) 0.81
Prevalence and risk factors for pulmonary hypertension in patients with hemoglobin E/β-thalassemia disease. Eur J Haematol (2014) 0.81
Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. Eur J Haematol (2008) 0.81
Detection of ICAM-1, ICAM-2, ICAM-3, PECAM-1 and VCAM-1, evaluation of hypercoagulable state and platelet aggregation in hemoglobinopathy patients with erythroblasts. Haematologica (2001) 0.80
Association of Iron Overload with Oxidative Stress, Hepatic Damage and Dyslipidemia in Transfusion-Dependent β-Thalassemia/HbE Patients. Indian J Clin Biochem (2013) 0.80
Quantification of siderophages in bronchoalveolar fluid in transfusional and primary pulmonary hemosiderosis. Pediatr Pulmonol (2006) 0.80
Pulmonary hypertension risk in patients with hemoglobin h disease: low incidence and absence of correlation with splenectomy. Acta Haematol (2013) 0.79
Long-term treatment with high-dose of sildenafil in a thalassemic patient with pulmonary hypertension. Monaldi Arch Chest Dis (2012) 0.79
Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. Br J Haematol (2015) 0.79
Cerebral thrombosis in patients with β-thalassemia: a systematic review. Blood Coagul Fibrinolysis (2012) 0.78
Thrombosis in thalassemia: why are we so concerned? Hemoglobin (2011) 0.78
Altered vascular function, arterial stiffness, and antioxidant gene responses in pediatric thalassemia patients. Pediatr Cardiol (2012) 0.77
Pulmonary arterial hypertension in a patient with β-thalassemia intermedia and reversal with infusion epoprostenol then transition to oral calcium channel blocker therapy: review of literature. Pulm Circ (2014) 0.76
Lupus anticoagulant and anticardiolipin antibodies in polytransfused beta thalassemia major. Hematology (2006) 0.76
Effect of genotype on pulmonary hypertension risk in patients with thalassemia. Eur J Haematol (2014) 0.76
Normalized coagulation markers and anticoagulation proteins in children with severe β-thalassemia disease after stem cell transplantation. Thromb Res (2011) 0.76
Magnetic resonance comparison of left-right heart volumetric and functional parameters in thalassemia major and thalassemia intermedia patients. Biomed Res Int (2015) 0.76
Pulmonary function tests in children with beta-thalassemia major. Chron Respir Dis (2007) 0.75
Management of pulmonary arterial hypertension associated to thalassemia: when pulmonary endarterectomy is the best therapeutical option? A case report. J Thromb Thrombolysis (2015) 0.75